181 related articles for article (PubMed ID: 36746095)
1. Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways.
Qin Y; Song D; Liao S; Chen J; Xu M; Su Y; Lian H; Peng H; Wei L; Chen K; Xu J; Zhao J; Liu Q
Biomed Pharmacother; 2023 Apr; 160():114347. PubMed ID: 36746095
[TBL] [Abstract][Full Text] [Related]
2. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
[No Abstract] [Full Text] [Related]
3. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
[TBL] [Abstract][Full Text] [Related]
4. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
[TBL] [Abstract][Full Text] [Related]
5. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
6. Dauricine attenuates ovariectomized-induced bone loss and RANKL-induced osteoclastogenesis via inhibiting ROS-mediated NF-κB and NFATc1 activity.
Lin X; Yuan G; Yang B; Xie C; Zhou Z; Liu Y; Liu Z; Wu Z; Akimoto Y; Li N; Xu R; Song F
Phytomedicine; 2024 Jul; 129():155559. PubMed ID: 38579642
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
8. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
9. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
10. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
11. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
12. Thiaplakortone B attenuates RANKL-induced NF-κB and MAPK signaling and dampens OVX-induced bone loss in mice.
Wang Q; Chen D; Wang Y; Dong C; Liu J; Chen K; Song F; Wang C; Yuan J; Davis RA; Kuek V; Jin H; Xu J
Biomed Pharmacother; 2022 Oct; 154():113622. PubMed ID: 36081291
[TBL] [Abstract][Full Text] [Related]
13. MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway.
Wang Y; Li X; Zhou S; Li J; Zhu Y; Wang Q; Zhao F
Oxid Med Cell Longev; 2022; 2022():7727006. PubMed ID: 36148414
[TBL] [Abstract][Full Text] [Related]
14. Corynoline Suppresses Osteoclastogenesis and Attenuates ROS Activities by Regulating NF-κB/MAPKs and Nrf2 Signaling Pathways.
Jin C; Yu XB; Yang J; Lin Z; Ma RX; Lin BH; Zhang HJ; Dai ZH; Xue K; Xie CL; Zheng W; Feng Y; Xiao J; Yang L
J Agric Food Chem; 2024 Apr; 72(14):8149-8166. PubMed ID: 38551844
[TBL] [Abstract][Full Text] [Related]
15. Myrislignan targets extracellular signal-regulated kinase (ERK) and modulates mitochondrial function to dampen osteoclastogenesis and ovariectomy-induced osteoporosis.
Yang T; Chen W; Gan K; Wang C; Xie X; Su Y; Lian H; Xu J; Zhao J; Liu Q
J Transl Med; 2023 Nov; 21(1):839. PubMed ID: 37993937
[TBL] [Abstract][Full Text] [Related]
16. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
17. GSK 650394 Inhibits Osteoclasts Differentiation and Prevents Bone Loss via Promoting the Activities of Antioxidant Enzymes
Jin LY; Huo SC; Guo C; Liu HY; Xu S; Li XF
Oxid Med Cell Longev; 2022; 2022():3458560. PubMed ID: 36164394
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone I attenuates estrogen-deficiency bone loss via inhibiting RANKL-induced MAPK and NF-κB signaling pathways.
Ma C; Wang Z; Mo L; Wang X; Zhou G; Yi C; Niu W; Liu Y
Int Immunopharmacol; 2024 Jan; 127():111322. PubMed ID: 38064814
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of NF-κB and ERK signaling pathways in osteoclasts and M1 macrophage polarization: Mechanistic insights into the anti-osteoporotic effects of Pseudolaric acid B.
Liu L; Xiang C; Li T; Zhao Z; Xiao T; Ouyang Z
Life Sci; 2024 May; 345():122592. PubMed ID: 38554947
[TBL] [Abstract][Full Text] [Related]
20. Surfactin suppresses osteoclastogenesis via the NF-κB signaling pathway, promotes osteogenic differentiation in vitro, and inhibits oestrogen deficiency-induced bone loss in vivo.
Kuang Z; Yang X; Cao Z; Li Y; Hu J; Hong X; Li B; Wu C; Qi Q; Liu X; Dai M
Int Immunopharmacol; 2023 Apr; 117():109884. PubMed ID: 36805201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
